Article
Sponsored Content
Author(s):
As competition in a diversifying specialty drug business rises to fiver pitch, manufacturers are seeking new ways to differentiate the product servicing model to help their brands stand out. Triplefin's Hub-Lite™ program is adapting to these new expectations with a customized set of services geared to specialty's biggest growth segment: mid-range therapies with higher price tags than traditional retail pharmacy but significantly lower than high-end specialty pharma.
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.